The ARM Foundation for Cell and Gene Medicine is dedicated to providing the education, information, and research needed to accelerate patient awareness of and access to transformative therapies.
Cell and gene medicine can produce life-changing therapies for patients suffering from incurable diseases. The ARM Foundation for Cell and Gene Medicine is dedicated to providing the education, information, and research needed to accelerate patient awareness of and access to these transformative therapies.
The Foundation is an independent, 501(c)(3) non-profit organization established in 2018 by the Alliance for Regenerative Medicine (ARM), the preeminent international advocacy organization for regenerative medicine and advanced therapies. The goal of the ARM Foundation for Cell and Gene Medicine is to educate, engage, and empower patients, caregivers, industry leaders, and other stakeholders to help advance the science and benefits of gene therapy, gene editing, cell therapy, tissue-engineering and organ regeneration.. It will accomplish this through educational and research projects that increase public awareness of the clinical and social benefits of gene medicine, which will help to expedite the development of life-saving therapies.
“Gene medicine will achieve its vast potential only when the public, patients, and caregivers understand and accept it as a safe and effective therapeutic option.”
Stewart Parker,
Board Chairperson for the ARM Foundation Foundation Programs and Projects
The Foundation has begun three initiatives led by Steering Committees of leading experts in the fields of health economics, public policy, communications, market access, manufacturing, precision medicine, and patient advocacy. These three programs are:
This multi-year program began in 2018 with extensive market research on public and patient/caregiver perceptions and attitudes about gene medicine. It will provide the public with accurate, jargon-free information about the science, benefits, limitations, and possible risks of therapeutic gene medicine technology and encourage news and social media influencers to cover gene medicine in a more balanced way with less emphasis on the sensational.
Planned program activities and content include:
The Foundation will conduct research that provides in-depth analyses of the impact of regenerative medicines on national and international healthcare economies. It also is planning to do a pharmaco-economic analysis using advanced economic simulation models of regenerative medicines in several major disease areas to quantify the value of curative therapies compared to the current standard of care.
This research project will identify and prioritize the infrastructure, logistics, and healthcare system requirements essential to support widespread adoption of these transformative medicines. It will explore in depth the components of these therapeutic platforms and how they could leverage manufacturing breakthroughs while integrating technologies such as next-gen sequencing, and other precision medicine tools in imaging and healthcare IT.
Nicole Boice
Founder, Global Genes
Cindy Collins
CEO, Editas
Amy Duross
CEO, Vineti
Don Gibbons
Consultant, DLG Strategic Communication
Ellen Feigal
Partner, NDA Partners, LLC
Alison Finger
Chief Commercial Officer, bluebird bio
Karin Hehenberger
Founder and CEO, Lyfebulb
Brett Kopelan
Executive Director, debra of America
Bethany Kraynack
VP Operations, ARM
Janet Lambert
CEO, ARM
Lin MacMaster
Head of Marketing and Communications, Inova Health Systems
Adrian McKemey
Managing Director and Head of R&D Strategy Solutions, IQVIA
Maria Millan
President & CEO, CIRM
David Nagler
Formerly of Audentes
Stewart Parker
Principal, Parker BioConsulting
Dennis Purcell
Founder, Senior Advisor, Aisling Partners
Brock Reeve
Executive Director, Harvard Stem Cell Institute
Martha Rook
SVP, Head of Manufacturing, Sigilon Therapeutics, Inc.
Morrie Ruffin
Executive Director, ARM Foundation
Frank Sasinowski
Hyman, Phelps and McNamara
Robin Smith
Stem for Life Foundation and CURA Foundation
Jennifer Mound Smoter
SVP, External Affairs & Communications, Intellia Therapeutics
Marshall Summar
MD, National Children’s Medical Center, NORD Board Chair
Phil Vanek
General Manager, Cell Therapy, GE Healthcare Life Sciences
Claudia Zylberberg
CEO, Akron Biotech
To learn more about the ARM Foundation, including partnerships and opportunities to support its programs, please contact Morrie Ruffin, mruffin@alliancerm.org.
Media contact:
Mariesa Kemble
(608) 850 4745
kemblem@mac.com
